AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12435255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BP goal (mean arterial pressure 92 mm Hg or less)
Number of subjects: 1094
Study 12435255 — intervention group
Group type: COMPARATOR
Intervention: Usual BP goal (mean arterial pressure 102 to 107 mm Hg)
Number of subjects: 1094
Study 12435255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5‐10 mg/d)
Number of subjects: 1094
Study 12435255 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50‐200 mg/d)
Number of subjects: 1094
Study 12435255 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5‐10 mg/d)
Number of subjects: 1094
Study 10626558 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dose of 0.1 IU/kg/day (0.033 mg/kg/day) for 2 years (Group A)
Number of subjects: 18
Study 10626558 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dose of 0.2 IU/kg/day (0.066 mg/kg/day) during the second year (Group B)
Number of subjects: 18
Study 10626558 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment restarted at a dose of 0.1 IU/kg/day (0.033 mg/kg/day) after a 6-month break
Number of subjects: 18
Study 10626558 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group, untreated for the first year)
Number of subjects: 18
Study 10626558 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (GH treatment withdrawn)
Number of subjects: 18
Study 7795941 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 0
Study 7795941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 0
Study 7795941 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational practice
Number of subjects: 0
Study 7795941 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual discrimination task practice
Number of subjects: 0
Study 7795941 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination of a nonspatial version of the criterion motion
Number of subjects: 0
Study 1951859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metrifonate (10 mg/kg for three doses each year)
Number of subjects: 2493
Study 1951859 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel therapy (40 mg/kg as a single dose each year)
Number of subjects: 2493
Study 1951859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control intervention mentioned)
Number of subjects: 2493
Study 7197489 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol, 2.5 mg IM
Number of subjects: 150
Study 7197489 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 100 mg IM
Number of subjects: 150
Study 7197489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 29805252 — intervention group
Group type: EXPERIMENTAL
Intervention: Active buprenorphine 5 µg/hour
Number of subjects: 162
Study 29805252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 29805252 — intervention group
Group type: EXPERIMENTAL
Intervention: Active buprenorphine
Number of subjects: 162
Study 28099979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone lactate (low dose: 20 mcg/kg bolus followed by 0.2 mcg/kg/minute)
Number of subjects: 6
Study 28099979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone lactate (standard dose: 50 mcg/kg bolus followed by 0.5 mcg/kg/minute)
Number of subjects: 6
Study 26268533 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg)
Number of subjects: 133
Study 26268533 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (50 mg)
Number of subjects: 133
Study 26268533 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 133
Study 26268533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 23239793 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft diet (SD)
Number of subjects: 60
Study 23239793 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet (CLD)
Number of subjects: 60
Study 21606084 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized echo-guided CRT
Number of subjects: 186
Study 21606084 — intervention group
Group type: COMPARATOR
Intervention: RV apical pacing
Number of subjects: 186
Study 18444738 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal stimulus exposure with a focus on evaluative tone
Number of subjects: 0
Study 18444738 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed concepts with extreme evaluative meaning
Number of subjects: 0
Study 16572266 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 16572266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15284369 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP)
Number of subjects: 14
Study 10405745 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 2 mL/kg of 300 mg iodine/mL contrast material at 5 mL/sec (Group 1)
Number of subjects: 126
Study 10405745 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 2 mL/kg of 300 mg iodine/mL contrast material at 3 mL/sec (Group 2)
Number of subjects: 126
Study 10405745 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 1.5 mL/kg of 300 mg iodine/mL contrast material at 5 mL/sec (Group 3)
Number of subjects: 126
Study 10405745 — intervention group
Group type: COMPARATOR
Intervention: Injection of 1.5 mL/kg of 300 mg iodine/mL contrast material at 3 mL/sec (Group 4)
Number of subjects: 126
Study 7563045 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief and information intervention
Number of subjects: 405
Study 7563045 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief intervention
Number of subjects: 405
Study 7563045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 405
Study 2127325 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS recommendations accepted 100% of the time
Number of subjects: 110
Study 2127325 — intervention group
Group type: COMPARATOR
Intervention: CPS recommendations accepted less than 100% of the time
Number of subjects: 110
Study 7373255 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous group patient education and family physician appointments
Number of subjects: 123
Study 7373255 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive individualized psychosocial counseling and family physician appointments
Number of subjects: 123
Study 7373255 — intervention group
Group type: COMPARATOR
Intervention: Family physician appointments only (baseline medical care)
Number of subjects: 123
Study 31811673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus acetaminophen
Number of subjects: 120
Study 31811673 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen plus placebo
Number of subjects: 120
Study 31870414 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced spectral mammography (CESM)
Number of subjects: 528
Study 31870414 — intervention group
Group type: COMPARATOR
Intervention: Conventional breast imaging techniques
Number of subjects: 528
Study 31870414 — intervention group
Group type: EXPERIMENTAL
Intervention: CESM
Number of subjects: 528
Study 28410922 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke Leaf Extract (ALE) 1800 mg (four tablets per day)
Number of subjects: 80
Study 28410922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch, lactose, and avicel, four tablets per day)
Number of subjects: 80
Study 27681579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib capsule (500 mg once daily on a 5-days-on/2-days-off schedule)
Number of subjects: 173
Study 27681579 — intervention group
Group type: COMPARATOR
Intervention: Dovitinib tablet (500 mg once daily on a 5-days-on/2-days-off schedule)
Number of subjects: 173
Study 27681579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (both formulations)
Number of subjects: 173
Study 25826793 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 33
Study 25826793 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 33
Study 25826793 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study 22154243 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic preparation containing 30μg ethinylestradiol and 150μg desogestrel (DG/EE)
Number of subjects: 44
Study 22154243 — intervention group
Group type: COMPARATOR
Intervention: Monophasic preparation containing 30μg ethinylestradiol and 150μg levonogestrel (LNG/EE)
Number of subjects: 44
Study 22154243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both COCs (DG/EE and LNG/EE)
Number of subjects: 44
Study 20223599 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid therapy (methylprednisolone)
Number of subjects: 36
Study 20223599 — intervention group
Group type: COMPARATOR
Intervention: Alternative therapy (mitoxantrone)
Number of subjects: 36
Study 20223599 — intervention group
Group type: COMPARATOR
Intervention: Major depression (MD) receiving antidepressants
Number of subjects: 36
Study 20223599 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 17668416 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hydroxybuspirone racemate (BMS-528215)
Number of subjects: 20
Study 17668416 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hydroxybuspirone S-enantiomer (BMS-442606)
Number of subjects: 20
Study 17668416 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hydroxybuspirone R-enantiomer (BMS-442608)
Number of subjects: 20
Study 17668416 — intervention group
Group type: COMPARATOR
Intervention: buspirone
Number of subjects: 20
Study 15878492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of thermal water (active group, n=20)
Number of subjects: 39
Study 15878492 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n=19)
Number of subjects: 39
Study 15878492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of thermal water (active group)
Number of subjects: 39
Study 15878492 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 39
Study 12025921 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation of the gastrocnemius muscle of the remaining leg, 2 hours per day for 8 weeks.
Number of subjects: 50
Study 12025921 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise program for patients with limb amputation (Control group).
Number of subjects: 50
Study 10465168 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (1 g daily, n=2836)
Number of subjects: 11324
Study 10465168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (n-3 PUFA and vitamin E, n=2830)
Number of subjects: 11324
Study 10465168 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg daily, n=2830)
Number of subjects: 11324
Study 10465168 — intervention group
Group type: COMPARATOR
Intervention: Control group (none, n=2828)
Number of subjects: 11324
Study 7797378 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude antigens from Trichinella spiralis in ELISA
Number of subjects: 3
Study 7797378 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot analysis for T. spiralis
Number of subjects: 3
Study 30527287 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherbal combination tablets
Number of subjects: 30
Study 30527287 — intervention group
Group type: COMPARATOR
Intervention: Turmeric tablets
Number of subjects: 30
Study 30527287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28096034 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral to inpatient treatment (SRIT) contract
Number of subjects: 53
Study 26742418 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH® MAC (MAC)
Number of subjects: 60
Study 26742418 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh Laryngoscope (McL)
Number of subjects: 60
Study 26742418 — intervention group
Group type: COMPARATOR
Intervention: Airwayscope® (AWS)
Number of subjects: 60
Study 26742418 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 26742418 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC and AWS groups
Number of subjects: 60
Study 23135962 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6 -174CC genotype in AMI group
Number of subjects: 102
Study 23135962 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14 -260TT genotype in AMI group
Number of subjects: 102
Study 23135962 — intervention group
Group type: COMPARATOR
Intervention: CD14 and IL6 variants
Number of subjects: 102
Study 22030384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5mg daily
Number of subjects: 3148
Study 22030384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3148
Study 19885409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride treatment (FTB)
Number of subjects: 27
Study 19885409 — intervention group
Group type: COMPARATOR
Intervention: Titanium dioxide grit-blasted (TB) implants
Number of subjects: 27
Study 17316373 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n=11)
Number of subjects: 23
Study 17316373 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (n=12)
Number of subjects: 23
Study 17316373 — intervention group
Group type: COMPARATOR
Intervention: Strength or endurance training
Number of subjects: 23
Study 15643795 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of antenatal care with fewer visits
Number of subjects: 0
Study 15643795 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care model
Number of subjects: 0
Study 11350556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine irrigation (40‐120 mL of 1:1,000,000 epinephrine)
Number of subjects: 173
Study 11350556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epinephrine irrigation)
Number of subjects: 173
Study 9390594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 5, 10, or 15 microg/kg
Number of subjects: 165
Study 9390594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 100 microg/kg
Number of subjects: 165
Study 9390594 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 5, 10, 30, or 50 microg/kg
Number of subjects: 165
Study 8193488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bovine surfactant (100 mg/kg birth weight)
Number of subjects: 90
Study 8193488 — intervention group
Group type: COMPARATOR
Intervention: Low-dose bovine surfactant (50 mg/kg birth weight)
Number of subjects: 90
Study 8193488 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 3300375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine, 2.5 mg twice daily
Number of subjects: 6
Study 3300375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31306084 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 with dihydroartemisinin-piperaquine plus a single low dose primaquine
Number of subjects: 193
Study 31306084 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 without antimalarial drugs
Number of subjects: 193
Study 31306084 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 with and without antimalarial drugs
Number of subjects: 193
Study 29460071 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D roadmap
Number of subjects: 30
Study 29460071 — intervention group
Group type: COMPARATOR
Intervention: CO2 wedged hepatic vein portography
Number of subjects: 30
Study 27412317 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fatty acid (SFA) diet
Number of subjects: 37
Study 27412317 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fatty acid (PUFA) diet
Number of subjects: 37
Study 27412317 — intervention group
Group type: COMPARATOR
Intervention: Low fatty acid diet
Number of subjects: 37
Study 27412317 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 37
Study 25327812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (500 mg) + Antacid (318 mg Al(3+) and 496 mg Mg(2+))
Number of subjects: 24
Study 25327812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (500 mg) + Antacid (4 hours after)
Number of subjects: 24
Study 25327812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (500 mg) + Antacid (2 hours before)
Number of subjects: 24
Study 25327812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (500 mg) + Ferrous sulfate (60 mg Fe(2+))
Number of subjects: 24
Study 25327812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (500 mg) + Calcium carbonate (600 mg Ca(2+))
Number of subjects: 24
Study 25327812 — intervention group
Group type: COMPARATOR
Intervention: Nemonoxacin (500 mg) alone
Number of subjects: 24
Study 22521072 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 755
Study 22521072 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 755
Study 20737683 — intervention group
Group type: EXPERIMENTAL
Intervention: INFLUVIR vaccine administered intranasally
Number of subjects: 30
Study 20737683 — intervention group
Group type: EXPERIMENTAL
Intervention: PANDEFLU vaccine administered intramuscularly
Number of subjects: 30
Study 20737683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 19923507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 9
Study 19923507 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 9
Study 16168872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking prevalence among men
Number of subjects: 1021
Study 16168872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking prevalence among women
Number of subjects: 1021
Study 16168872 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of smoking initiation
Number of subjects: 1021
Study 12875144 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-with-adherence intervention (individualized graphic feedback on exercise goals and participation, problem-solving support by nurses)
Number of subjects: 16
Study 12875144 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only group
Number of subjects: 16
Study 10714789 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antibiotics (macrolides and quinolones)
Number of subjects: 0
Study 10714789 — intervention group
Group type: COMPARATOR
Intervention: Conventional antimicrobial therapy (beta-lactam therapy)
Number of subjects: 0
Study 8684787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 399
Study 8684787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 1831006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day
Number of subjects: 8245
Study 1831006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day
Number of subjects: 8245
Study 1831006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg/day
Number of subjects: 8245
Study 1831006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245
Study 1831006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20-40 mg/day)
Number of subjects: 8245
Study 1831006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day)
Number of subjects: 8245
Study 1831006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (80 mg/day)
Number of subjects: 8245
Study 6861303 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (daily prescribed physical exercise for 60 days)
Number of subjects: 12
Study 6861303 — intervention group
Group type: COMPARATOR
Intervention: Control group (resumed customary activities)
Number of subjects: 12
Study 6861303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 12
Study 31155473 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie tracking app
Number of subjects: 124
Study 31155473 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable Bite Counter device
Number of subjects: 124
Study 31155473 — intervention group
Group type: EXPERIMENTAL
Intervention: Kcal tracking app
Number of subjects: 124
Study 31155473 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo meal app
Number of subjects: 124
Study 29746823 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-change intervention (weekly 30-minute telephone sessions for 12 weeks)
Number of subjects: 38
Study 29746823 — intervention group
Group type: COMPARATOR
Intervention: Attention control (CTL; health status monitoring sessions)
Number of subjects: 38
Study 26733186 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention (24-week duration)
Number of subjects: 859
Study 26733186 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 859
Study 26733186 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 859
Study 24671907 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD (Sativex®)
Number of subjects: 0
Study 24671907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22657586 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized DRI-covering low-calorie formula diet over three months (n=32)
Number of subjects: 104
Study 22657586 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline micronutrient intake (dietary record collection)
Number of subjects: 104
Study 22657586 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 104
Study 20674983 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine treatment
Number of subjects: 117
Study 20674983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 117
Study 20674983 — intervention group
Group type: COMPARATOR
Intervention: Control group (106 individuals)
Number of subjects: 117
Study 17180128 — intervention group
Group type: EXPERIMENTAL
Intervention: Test solution (sterile, isotonic solution patterned after human amniotic fluid), 2.5 ml/kg every 3 hours via OG/NG tube for up to 7 days.
Number of subjects: 20
Study 17180128 — intervention group
Group type: COMPARATOR
Intervention: Sham administration (control), every 3 hours via OG/NG tube for up to 7 days.
Number of subjects: 20